Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

0.4073 -0.1227 (-23.15%)
Streaming Delayed Price Updated: 2:48 PM EDT, Jul 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
32 33 Next >
News headline image
Lexaria Granted Important New Oral Nicotine Patent
Newest granted patent expands worldwide patent portfolio to 24 KELOWNA, BC / ACCESSWIRE / March 8, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
News headline image
Studies Advance Lexaria Bioscience's Tech For Improving Pharmaceutical Drugs ↗
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience is dedicated to... 
Via Benzinga
Studies Advance Lexaria Bioscience’s (NASDAQ: LEXX) Tech for Improving Pharmaceutical Drugs
Via Investor Brand Network
News headline image
Lexaria's DehydraTECH(TM) Demonstrates Faster Delivery Of Sildenafil ↗
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience Corp. (NASDAQ: LEXX)... 
Via Benzinga
Lexaria’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates Faster Delivery of Sildenafil
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates Faster, Higher Overall Delivery of Sildenafil into Bloodstream
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates Faster, Higher Overall Delivery of Sildenafil into Bloodstream
Via Investor Brand Network
News headline image
Lexaria Bioscience Optimistic Of Positive Study Results ↗
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.... 
Via Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Optimistic of Positive Study Results
Via Investor Brand Network
As It Targets Multiple Large Market Opportunities, Lexaria Bioscience Corp. (NASDAQ: LEXX) Is Leveraging Elaborate Studies to Progressively Remove Risks Associated with Commercialization, Regulation
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Optimistic of Positive Study Results, Eyes ‘Most Exciting Year Ever’
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Optimistic of Positive Study Results, Eyes ‘Most Exciting Year Ever’
Via Investor Brand Network
News headline image
Lexaria Optimistic About Expanded DehydraTECH Investigations ↗
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria just announced ground-breaking... 
Via Benzinga
Lexaria (NASDAQ: LEXX) Optimistic About Expanded DehydraTECH Investigations
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Optimistic About its Expanded DehydraTECH Investigations; Plans for More Studies in 2022
Via Investor Brand Network
News headline image
Lexaria World Leader Through DehydraTECH(TM) – Its Pioneering Drug Delivery Tech ↗
Photo by Shelby Ireland on Unsplash 
Via Benzinga
Lexaria (NASDAQ: LEXX) World Leader Through DehydraTECH(TM) – Its Pioneering Drug Delivery Tech
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Is World Leader Through DehydraTECH(TM) – Its Pioneering Drug Delivery Technology
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Is World Leader Through DehydraTECH(TM) – Its Pioneering Drug Delivery Technology
Via Investor Brand Network
News headline image
Following Sildenafil Study, Lexaria Announces Plans For More Studies In 2022 ↗
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria’s animal study could be... 
Via Benzinga
Following Sildenafil Study, Lexaria (NASDAQ: LEXX) Announces Plans for More Studies in 2022
Via Investor Brand Network
Following Successful Sildenafil Animal Study, Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Plans for More Studies in 2022
Via Investor Brand Network
News headline image
Lexaria's DehydraTECH(TM) To Be Evaluated As Treatment For Multiple Conditions ↗
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience Corp. (NASDAQ: LEXX)... 
Via Benzinga
Lexaria’s (NASDAQ: LEXX) DehydraTECH(TM) to Be Evaluated as Treatment for Multiple Conditions
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) to Be Evaluated for Potential Treatment Options for Multiple Conditions
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) to Be Evaluated for Potential Treatment Options for Multiple Conditions
Via CannabisNewsWire
News headline image
Lexaria Technology Shows Promise In Improving Performance Of ED Drugs ↗
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Health and wellness drug bio-... 
Via Benzinga
Lexaria (NASDAQ: LEXX) Technology Shows Promise in Improving Performance of ED Drugs
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Technology Shows Promise in Improving Performance, Speed of ED Drugs
Via Investor Brand Network
News headline image
Lexaria CEO Summarizes 2021 Milestones in Letter to Shareholders ↗
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. In 2021, Lexaria conducted several main studies evaluating... 
Via Benzinga
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.